MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21 (Korea Bizwire) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based [...]
HONG KONG and BOSTON, May 3 (Korea Bizwire) — Zenas BioPharma (“Zenas”), a cross-border (China-USA based) biopharmaceutical company committed to the development and delivery of immune-based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative [...]
HONG KONG and BOSTON, March 23 (Korea Bizwire) — Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds [...]